Measles-containing-vaccine second-dose (MCV2) immunization coverage in Costa Rica
Costa Rica: Measles-containing-vaccine second-dose (MCV2) immunization coverage was 92.0% in 2025. ◆ Volatile
Measles-containing-vaccine second-dose (MCV2) immunization coverage in Costa Rica, 2000–2025
Source: World Health Organization, Global Health Observatory.
Analysis
Costa Rica recorded 92.0% for measles-containing-vaccine second-dose (mcv2) immunization coverage in 2025.
Compared with earlier readings it is up 5.7% on the previous year and up 2.2% over ten years.
Over the whole period, measles-containing-vaccine second-dose (mcv2) immunization coverage in Costa Rica peaked at 95.0% in 2012 and was at its lowest, 0.0%, in 2000.
That places Costa Rica 56th out of 194 countries with data for 2025, putting it in the middle of the range.
The series is highly variable year to year, so single readings are best treated with caution.
Measles-containing-vaccine second-dose (MCV2) immunization coverage in Costa Rica, year by year
| Year | Value | Change |
|---|---|---|
| 2000 | 0.0% | — |
| 2001 | 0.0% | — |
| 2002 | 0.0% | — |
| 2003 | 0.0% | — |
| 2004 | 0.0% | — |
| 2005 | 0.0% | — |
| 2006 | 0.0% | — |
| 2007 | 0.0% | — |
| 2008 | 89.0% | — |
| 2009 | 84.0% | -5.6% |
| 2010 | 79.0% | -6.0% |
| 2011 | 80.0% | +1.3% |
| 2012 | 95.0% | +18.8% |
| 2013 | 92.0% | -3.2% |
| 2014 | 90.0% | -2.2% |
| 2015 | 90.0% | +0.0% |
| 2016 | 87.0% | -3.3% |
| 2017 | 93.0% | +6.9% |
| 2018 | 93.0% | +0.0% |
| 2019 | 93.0% | +0.0% |
| 2020 | 81.0% | -12.9% |
| 2021 | 69.0% | -14.8% |
| 2022 | 75.0% | +8.7% |
| 2023 | 83.0% | +10.7% |
| 2024 | 87.0% | +4.8% |
| 2025 | 92.0% | +5.7% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 17.3% | 0.0% | 89.0% | 10 |
| 2010s | 89.2% | 79.0% | 95.0% | 10 |
| 2020s | 81.2% | 69.0% | 92.0% | 6 |
Countries ranked near Costa Rica
More health data for Costa Rica
- Un projection of annual infant deaths, annual growth rate -2.78 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.4617 % change on previous year (2090)
- Heat deaths vs projected death rates 1,632 (2090)
- Un projection of annual infant deaths 35 (2100)
- Population ages 0-14, female, annual growth rate -2.17 % change on previous year (2025)
- Population ages 0-14, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 0-14, female, per capita 0.0896 units per person (2025)
- Population ages 0-14, male, annual growth rate -2.18 % change on previous year (2025)
- Population ages 0-14, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 0-14, male, per capita 0.0935 units per person (2025)
Frequently asked questions
- What is measles-containing-vaccine second-dose (mcv2) immunization coverage in Costa Rica?
- Measles-containing-vaccine second-dose (mcv2) immunization coverage in Costa Rica was 92.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest measles-containing-vaccine second-dose (mcv2) immunization coverage recorded in Costa Rica?
- The highest recorded value was 95.0% in 2012.
- What is the lowest measles-containing-vaccine second-dose (mcv2) immunization coverage recorded in Costa Rica?
- The lowest recorded value was 0.0% in 2000.
- How does Costa Rica rank for measles-containing-vaccine second-dose (mcv2) immunization coverage?
- Costa Rica ranks 56th out of 194 countries with data for 2025.
- Is measles-containing-vaccine second-dose (mcv2) immunization coverage rising or falling in Costa Rica?
- Over the last ten years it is up 2.2%. The long-run trend across the full record is volatile.
- Where does this Costa Rica data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Measles-containing-vaccine second-dose (MCV2) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 26 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).